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OBJECTIVE To examine trends in bladder cancer survival among whites, blacks, Hispanics, and Asian/Pacific
Islanders in the United States over a 30-year period. Racial disparities in bladder cancer
outcomes have been documented with poorer survival observed among blacks. Bladder cancer
outcomes in other ethnic minority groups are less well described.
METHODS From the Surveillance, Epidemiology and End Results cancer registry data, we identified patients
diagnosed with transitional cell carcinoma of the bladder between 1975 and 2005. This cohort
included 163,973 white, 7731 black, 7364 Hispanic, and 5934 Asian/Pacific Islander patients.
We assessed the relationship between ethnicity and patient characteristics. Disease-specific
5-year survival was estimated for each ethnic group and for subgroups of stage and grade.
RESULTS Blacks presented with higher-stage disease than whites, Hispanics, and Asian/Pacific Islanders,
although a trend toward earlier-stage presentation was observed in all groups over time. Five-year
disease-specific survival was consistently worse for blacks than for other ethnic groups, even
when stratified by stage and grade. Five-year disease-specific survival was 82.8% in whites
compared with 70.2% in blacks, 80.7% in Hispanics, and 81.9% in Asian/Pacific Islanders. There
was a persistent disease-specific survival disadvantage in black patients over time that was not
seen in the other ethnic groups.
CONCLUSION Ethnic disparities in bladder cancer survival persist between whites and blacks, whereas survival
in other ethnic minority groups appears similar to that of whites. Further study of access to care,
quality of care, and treatment decision making among black patients is needed to better
understand these disparities. UROLOGY 78: 544–549, 2011.
© 2011 Published by Elsevier Inc. Open access under CC BY-NC-ND license.Bladder cancer incidence and survival vary amongethnic groups.1-3 Prior studies demonstrate lowerincidence and poorer survival in blacks compared
with whites.4-6 Although much of the difference in sur-
ival has been attributed to higher stage at presentation
n blacks,5,6 this disparity persists between whites and
blacks with similar stage, grade, and treatment.7 Research
regarding bladder cancer outcomes in other ethnic
groups, such as Hispanics and Asian/Pacific Islanders
(APIs), is limited.
The objective of this study was to evaluate trends in
bladder cancer presentation and disease-specific survival
(DSS) in whites, blacks, Hispanics, and APIs between
1975 and 2005. Given increased health care awareness,
improved socioeconomic conditions, and improved ac-
cess to health care during this time period, we hypothe-
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would decrease over time.
MATERIAL AND METHODS
Data Source
We used data from the Surveillance, Epidemiology and End
Results (SEER) program, a consortium of population-based
cancer registries sponsored by the National Cancer Institute.
SEER collects information on patient and disease characteris-
tics and first course of treatment, with active follow-up for vital
status and cause of death (http://seer.cancer.gov).8 In 1975,
SEER included the states of Connecticut, Iowa, New Mexico,
Utah, and Hawai’i, the 13-county Seattle-Puget Sound area,
and the metropolitan areas of Atlanta, Detroit, and San Fran-
cisco-Oakland. By 2001, the SEER Program had gradually ex-
panded coverage to include California, New Jersey, Kentucky,
and Louisiana, as well as Native Americans residing in Arizona,
the Alaskan Native populations residing in Alaska, and 10
predominantly black rural counties in Georgia.8
The SEER areas currently cover more than 25% of the US
population and include 23% of blacks, 40% of Hispanics, 42% of
Native Americans and Alaska Natives, 53% of Asians, and 70% of
Hawaiian/Pacific Islanders.8 The SEER standard for case ascertain-
ment is 98%. To review the trends in bladder cancer over time,
5-year intervals were established beginning in 1975. The most
recent interval, 2000–2005, included 6 years of review.
0090-4295/11
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Study Cohort
We identified all patients in SEER diagnosed with transitional
cell carcinoma of the bladder (8120.2, 8120.3, 8121.2, 8122.3,
8130.2, 8130.3, 8131.2, 8131.3) between 1975 and 2005 whose
race and stage at diagnosis were known. In SEER, race/ethnicity
is determined from medical records and registration information
for each individual.
Disease-Specific Survival
DSS was defined as the time from initial diagnosis to the time
of death attributed to bladder cancer. SEER collects informa-
tion on underlying cause of death from the state death certifi-
cate.8
Covariates
In addition to race/ethnicity, we examined a number of patient
and disease characteristics. In the absence of individual-level
data on socioeconomic status, we used the median household
income in the census tract of residence. Urban vs rural resi-
dence was based on US Census Bureau designations for these
areas. Tumor stage was defined as localized for organ-confined
tumors, regional for tumors with extravesical extension or re-
gional lymph nodes, and distant for patients with visceral me-
tastases or nodal involvement above the pelvic brim. Advanced
stage was defined as regional- or distant-stage disease at presen-
tation. Primary treatment, ascertained from SEER data on the
first course of cancer-directed therapy, was categorized as sur-
gery only, radiation therapy only, both, or other. “Other” treat-
ment included strategies that did not involve surgery or radia-
tion therapy, such as observation or systemic chemotherapy.
Statistical Analysis
Chi-square tests were used to evaluate unadjusted associations
between race/ethnicity and other demographic and clinical
characteristics. We used Poisson regression to determine
whether there were differences across racial groups in the pro-
portion of advanced-stage cases over the course of the study.
Proportional hazards regression models were used to examine
the relationship between disease-specific death and race/ethnic-
ity, adjusting for sociodemographic and disease characteristics.
Two-way interactions between ethnicity and other covariates
were explored. All P values were two-sided, and P .05 was
considered statistically significant. Statistical analyses were per-
formed in SAS (version 9.1, Cary, NC).
RESULTS
Cohort Characteristics
We identified 163,973 white, 7731 black, 7364 Hispanic,
and 5934 API patients diagnosed with bladder cancer in
1975–2005 (Table 1). There were 1329 patients of other
(n  381) or unknown (n  948) race/ethnicity who
were excluded. Of the 185,002 patients in the study
cohort, 55,964 (30%) were younger than 65 years of age
at the time of diagnosis. Black patients were less likely to
be married (47%) at the time of bladder cancer diagnosis
compared with whites (65%), Hispanics (62%), and APIs
(70%).
Surgery was the predominant treatment modality
among all ethnic groups. Radiation was used infre-
quently and when given, it was usually used in con-
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ward increasing use of surgery alone was observed in all
racial/ethnic groups over time, blacks were less likely
to have surgery alone and more likely to receive ra-
diotherapy than whites, Hispanics, and APIs in each
time period.
Blacks were more likely to present with advanced-stage
disease (31%) than whites (21%), Hispanics (24%), and
APIs (23%) (P .001 for comparisons of black vs white,
black vs Hispanic, and black vs API difference between
1975–1979 and 2000–2005).
Higher rates of poorly differentiated and undifferenti-
ated grades at tumor presentation were observed in black
(47%) and API (46%) patients compared with white
(39%) and Hispanic (40%) patients (P .001 for com-
parison of black vs white and black vs Hispanic in dif-
ference between 1975–1979 and 2000–2005). Over time,
the percentage of patients with poorly differentiated or
undifferentiated disease increased among all ethnic
groups, particularly among Hispanics (27–43%), APIs
(37–49%), and whites (33–44%).
Survival
With a median follow-up of 4.2 years (interquartile range
1.7–8.6 years), blacks had poorer DSS than other ethnic
groups (Fig. 1). DSS was similar for whites, Hispanics,
and APIs.
The survival disparity for black patients persisted
within strata of disease stage and tumor grade (Table 2).
The greatest racial disparities were observed among pa-
tients with local and regional stage disease and those with
poorly differentiated and undifferentiated disease. For
example, in those with regional disease, 5-year DSS was
50.3% in whites compared with 41.5% in blacks—an
absolute difference of 8.8%. In those with poorly differ-
entiated disease, 5-year DSS was 67.7% in whites com-
pared with 51.9% in blacks—an absolute difference of
15.8%. In examining cohorts of patients by time period of
diagnosis, there was a persistent DSS disadvantage in
black patients over time that was not seen in the other
ethnic groups. However, DSS improved for all ethnic
groups, with the greatest improvement for localized stage
tumors in black patients (from 76.2% in 1975–1979 to
85.9% in 2000–2005).
In multivariable analysis, black patients had a higher
likelihood of disease-specific death, adjusting for age,
gender, marital status, census tract, median household
income, urban residence, year of diagnosis, geographic
area, pathologic stage, and grade and treatment (Table
3). With the exception of urban residence, these covari-
ates were also themselves significantly associated with
disease-specific mortality. Cancer stage (hazard ratio
[HR] 15.97; 95% CI 15.30–16.67; P .0001) and grade
(HR 5.90; 95% CI 5.49–6.33, P .001) were strong
predictors of cancer-specific death.
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Our study provides an initial description and highlights
important differences in bladder cancer survival among
multiple ethnic groups. In particular, Hispanics and APIs
had similar DSS compared with whites. Historically, re-
search specific to the health of other minorities has been
limited.9 A 2003 study showed that the federal govern-
ent has scant data on the health of APIs and only 0.2%
f federal grants from 1986–2000 involved API health
irectly or tangentially.10
Despite a modest improvement over time in DSS, we
Table 1. Patient Characteristics Stratified by Ethnicity for
White
n  163,973
n (%)
Age at diagnosis (yrs)
50 9522 (6)
50–59 20,888 (13)
60–69 41,343 (25)
70–79 54,771 (33)
80 37,449 (23)
Gender
Male 123,727 (75)
Female 40,246 (25)
Marital status
Married 107,565 (65)
Not married 50,388 (31)
Unknown 6020 (4)
Median income (quartiles)
Highest quartile 42,011 (26)
3rd quartile 42,398 (26)
2nd quartile 38,017 (23)
Lowest quartile 41,541 (25)
Urban residence
Metro 142,572 (87)
Nonmetro 21,395 (13)
Year of diagnosis
1975–1979 12,734 (8)
1980–1989 32,373 (20)
1990–1999 48,722 (30)
2000–2005 70,144 (43)
Geographic area
Northeast 33,028 (20)
South 14,480 (9)
Midwest 38,465 (23)
West 78,000 (48)
Pathologic stage
Localized 129,933 (79)
Regional 29,703 (18)
Distant 4337 (3)
Pathologic grade
Well differentiated 28,484 (17)
Moderately differentiated 60,445 (37)
Poorly differentiated 44,531 (27)
Undifferentiated 18,932 (12)
Unknown 11,581 (7)
Primary treatment
Surgery only 146,785 (91)
Radiation only 640 (1)
Surgery  radiation 8738 (5)
Other 5614 (3)
P values are  0.001 for all characteristics.
Such as observation or systemic chemotherapy “Other” treatmobserved a persistent disparity for black patients with
546bladder cancer. Five-year DSS was consistently worse for
blacks than for patients of other races/ethnicities, even
when stratified by stage and grade and adjusted for other
patient characteristics and primary therapy. These find-
ings support a recent SEER study that reported an excess
hazard of death from bladder cancer among blacks despite
adjusting for age, stage, and grade.11
Tumor stage at diagnosis is an independent predictor
of bladder cancer survival.12,13 Although a stage disparity
persists between blacks and other ethnic groups, the gap
has narrowed somewhat over the last 30 years. Black
Bladder Cancer Patients Diagnosed 1975–2005
Black
n  7731
Hispanic
n  7364
API
n  5934
n (%) n (%) n (%)
624 (8) 727 (10) 387 (6)
1202 (16) 1074 (15) 723 (12)
2030 (26) 1933 (26) 1423 (24)
2416 (31) 2235 (30) 2047 (34)
1459 (19) 1395 (19) 1354 (23)
5149 (67) 5456 (74) 4472 (75)
2582 (33) 1908 (26) 1462 (25)
3591 (47) 4581 (62) 4166 (70)
3800 (49) 2537 (34) 1601 (27)
340 (4) 246 (3) 167 (3)
1379 (18) 1772 (24) 1193 (20)
1691 (22) 1042 (14) 2930 (49)
1793 (23) 2994 (41) 1584 (27)
2868 (37) 1555 (21) 226 (4)
7491 (97) 6853 (93) 5761 (97)
240 (3) 510 (7) 172 (3)
479 (6) 251 (3) 257 (4)
1314 (17) 743 (10) 838 (14)
2372 (31) 2208 (30) 2142 (36)
3566 (46) 4162 (57) 2697 (45)
1030 (13) 1004 (14) 200 (3)
1623 (21) 162 (2) 75 (1)
2262 (29) 222 (3) 88 (1)
2816 (37) 5976 (81) 5571 (94)
5329 (69) 5629 (76) 4567 (77)
1947 (25) 1444 (20) 1147 (19)
455 (6) 291 (4) 220 (4)
1062 (14) 1224 (16) 833 (14)
2396 (31) 2705 (37) 1981 (33)
2482 (32) 1960 (27) 1812 (31)
1132 (15) 987 (13) 880 (15)
659 (8) 488 (7) 428 (7)
6363 (84) 6643 (91) 5277 (89)
99 (1) 31 (1) 48 (1)
626 (8) 314 (4) 351 (6)
505 (7) 326 (4) 224 (4)
ncluded strategies that did not involve surgery or radiation therapySEERpatients today are more likely to present with localized
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in the most recent time period we evaluated, the 70%
rate of localized disease in blacks was still less than the
rate of 79% observed in whites.
A disparity in tumor grade was also observed in this
cohort. In each time period, black and API patients
presented with higher-grade tumors than white patients.
We also observed a trend toward increasing rates of
poorly differentiated and undifferentiated disease among
all ethnic groups. The etiology of this trend is unclear
because the percentage of patients with unknown grade
remained relatively stable and thus may not be attribut-
able to improved pathology reporting.
A disparity between blacks and whites in 5-year DSS
persisted even when comparing patients of similar stage
and grade. The disparity was more marked in patients
with localized and regional stage disease; poorer survival
in these disease stages may reflect treatment delay during
a critical period where curative therapy is possible.4 The
maller survival disparity between black and white pa-
ients with distant-stage bladder cancer likely reflects the
oorer prognosis associated with metastatic bladder can-
er.
Marital status was also an independent predictor of
Figure 1. DSS by ethnicity for SEER bladder cancer pa-
ients diagnosed 1975–2005.
Table 2. Five-Year Disease-Specific Survival in SEER Blad-
der Cancer Patients Diagnosed 1975–2005
% 5-year DSS
White Black Hispanic API
All 82.8 70.2 80.7 81.9
Pathologic stage
Localized 92.1 85.9 91.6 92.7
Regional 50.3 41.5 49.7 51.3
Distant 8.4 7.4 7.5 8.2
Pathologic grade
Well differentiated 97.3 94.2 97.6 97.7
Moderately differentiated 92.7 86.7 92.2 93.0
Poorly differentiated 67.7 51.9 62.4 70.6
Undifferentiated 58.1 48.2 57.6 60.4SS. Gore et al demonstrated that marriage was associ-
UROLOGY 78 (3), 2011ted with improved survival in 7262 patients treated with
adical cystectomy for bladder cancer.14 Marital status
has also been associated with cancer survival in other
settings.15 The nearly 20% higher marriage rate in
whites, Hispanics, and APIs compared with blacks might
contribute to improved survival through several mecha-
nisms. A spouse may encourage more prompt evaluation
Table 3. Multivariable Analysis of Cancer-Specific Death
for SEER Bladder Cancer Patients Diagnosed 1975–2005
Variable HR (95% CI) P value
Age at diagnosis
(years)
.0001
50 Referent
50–59 1.36 (1.25–1.47)
60–69 1.75 (1.63–1.89)
70–79 2.34 (2.17–2.51)
80 3.78 (3.51–4.07)
Ethnicity .0001
White Referent
Black 1.29 (1.24–1.36)
Hispanic 1.03 (0.97–1.10)
API 0.95 (0.89–1.02)
Gender .0001
Male Referent
Female 1.06 (1.03–1.09)
Marital status .0001
Married Referent
Not married 1.26 (1.23–1.29)
Median income .0001
Highest quartile Referent
3rd quartile 1.02 (0.98–1.05)
2nd quartile 1.10 (1.06–1.14)
Lowest quartile 1.10 (1.05–1.14)
Urban residence .02
Metro Referent
Nonmetro 0.95 (0.91–0.99)
Geographic area .0001
Northeast Referent
South 1.02 (0.97–1.07)
Midwest 1.01 (0.96–1.05)
West 0.95 (0.91–0.98)
Pathologic stage .0001
Localized Referent
Regional 4.07 (3.95–4.19)
Distant 15.97 (15.30–16.67)
Pathologic grade .0001
Well differentiated Referent
Moderately
differentiated
2.24 (2.09–2.40)
Poorly differentiated 5.21 (4.87–5.58)
Undifferentiated 5.90 (5.49–6.33)
Unknown 3.59 (3.32–3.88)
Year of diagnosis .0001
1975–1979 Referent
1980–1989 0.83 (0.80–0.87)
1990–1999 0.74 (0.71–0.77)
2000–2005 0.73 (0.70–0.77)
Primary treatment .0001
Surgery Referent
Surgery  radiation 1.37 (1.32–1.41)
Radiation only 2.06 (1.89–2.24)
Other 2.11 (1.99–2.22)of symptoms, leading to an earlier diagnosis; provide
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Tpsychosocial support, promote smoking cessation; and
advocate for care in higher-quality facilities.14
Currently, no clear genetic differences or tumors with
poor prognostic molecular markers have been identified
that correlate with more aggressive bladder cancer in
blacks. However, ethnic differences in tobacco use have
been observed, which are associated with disparities in
bladder cancer incidence and, possibly, survival. Accord-
ing to the 1999–2001 National Survey on Drug Use and
Health, cigarette smoking was approximately 40% less
common in adult APIs than in adult whites and blacks.16
Hispanics also had an approximately 50% lower average
annual prevalence of cigarette smoking than whites in
the 1994–1996 National Health Interview Survey.17 A
systematic review showed that smoking significantly al-
ters patient prognosis after treatment for bladder carci-
noma.18 Thus, lower smoking rates among Hispanics and
APIs compared with blacks may in part explain their
higher DSS.
Disproportionate application of treatments may also
contribute to survival disparities between black and
white patients. Previous studies have reported that blacks
are more likely to receive radiation,19 radiation and che-
otherapy,20 or no treatment21 for bladder cancer com-
pared with whites. We did not detect any ethnic dispar-
ities in the use of chemotherapy. Recently, Hollenbeck et
al reported racial differences in initial treatment of early-
stage bladder cancer using SEER-Medicare data from
1992–2002.22 However, after the authors adjusted for
these differences in initial treatment intensity and in the
provider responsible for the bladder cancer care, the
differences failed to account for the greater risk of death
in black patients compared with white patients.22
In a cohort of Medicare beneficiaries, Schrag et al also
demonstrated that a higher socioeconomic status was
associated with a greater likelihood of cystectomy in
patients with muscle-invasive bladder cancer.23 Re-
cently, investigators have established an association be-
tween ethnicity and surgical outcomes after cystectomy,
where black patients had greater mortality and longer
hospitalization than did white patients undergoing cys-
tectomy.24,25 These differences in outcomes may be as-
sociated with differences in hospital volume, because
several studies have demonstrated lower mortality after
cystectomy in high-volume hospitals.26,27 In a recent
tudy, blacks were less likely to undergo cystectomy at a
igh-volume hospital, thereby placing them at a higher
isk of postoperative complications.24 Race may also be a
predictor of adherence to surveillance among patients
with superficial bladder cancer.28 Compared with 17% of
hite patients, almost 30% of black patients and patients
f other races had substandard follow-up.
Several limitations in our study should be acknowl-
dged. The SEER program expanded both in size and
eography during the study period, thus the racial/ethnic
isparities we observed may reflect sociodemographic
hanges over time in the SEER registries. Race-specific
548ladder cancer incidence estimates have been stable over
ime in SEER. Use of SEER historic staging is a less
recise alternative to tumor-node-metastasis pathologic
taging used in clinical decision making. However, the
atter was not available for cases diagnosed before 1988
nd the former sufficiently distinguished organ-confined
rom non–organ-confined disease. Also, although we as-
essed variation in primary treatment and its relationship
o both ethnicity and DSS, we had no information on
ubsequent cancer-directed therapy and the incidence
nd treatment of recurrent disease. Other potential con-
ounders, such as surveillance after primary therapy, were
ot available for analysis.
An important limitation of the SEER database is the
ack of information on patient comorbidity and hospital
olume, factors that are associated with adverse outcomes
fter radical cystectomy and that may influence diagnosis
nd treatment.26,27,29 Although this information may be
upplemented by analyzing cases in the linked SEER-
edicare database, that data source is limited to patients
ged 65 years or older. Although bladder cancer is pri-
arily considered a disease of the elderly, with the me-
ian age at diagnosis of transitional cell carcinoma being
9 years in males and 71 years in females,3 30% of bladder
cancer patients in our study were under age 65.
A final limitation is the lack of patient-level measures
of socioeconomic status, an important potential con-
founder because ethnicity may be a surrogate for socio-
economic status.30 In our analysis, the bottom 2 quartiles
of census tract median income were associated with a
higher risk of cancer-specific death, suggesting that lower
socioeconomic status also has a deleterious effect on
survival outcomes.
CONCLUSIONS
In conclusion, the rate of bladder cancer survival in
Hispanics and APIs appears to be similar to that of
whites. However, DSS disparities persist between whites
and blacks and are not fully explained by differences in
disease presentation and receipt of treatment. Although
stage at diagnosis and DSS improved over time in all
racial/ethnic groups, blacks were consistently more likely
to die from their disease. Factors that may explain sur-
vival disparities include variation in quality and timing of
primary therapy, surveillance after primary therapy, treat-
ment of recurrent disease, comorbidity, and tumor biol-
ogy. Further investigation of the role of these factors is
needed to better understand and eliminate the persistent
disparities in bladder cancer outcomes.
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